High Affinity Nerve Growth Factor Receptor - Pipeline Review, H1 2018

  • ID: 4540600
  • Drug Pipelines
  • 109 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • Array BioPharma Inc
  • Daiichi Sankyo Co Ltd
  • Genzyme Corp
  • Ignyta Inc
  • Merck & Co Inc
  • Plexxikon Inc
  • MORE
High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140 TrkA or NTRK1 or EC 2.7.10.1) - Pipeline Review, H1 2018

Summary:

High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140 TrkA or NTRK1 or EC 2.7.10.1) - Tropomyosin receptor kinase A or high affinity nerve growth factor receptor is a protein encoded by the NTRK1 gene. High affinity receptor for NGF bind and be activated by NTF3/neurotrophin-3. Upon dimeric NGF ligand-binding undergoes homodimerization, autophosphorylation and activation. It phosphorylates and/or activates several downstream effectors including SHC1, FRS2, SH2B1, SH2B2 and PLCG1 that regulate distinct overlapping signaling cascades driving cell survival and differentiation.

High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140 TrkA or NTRK1 or EC 2.7.10.1) pipeline Target constitutes close to 24 molecules. Out of which approximately 20 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 5, 2, 7 and 4 respectively.

Similarly, the universities portfolio in IND/CTA Filed and Preclinical stages comprises 1 and 3 molecules, respectively. Report covers products from therapy areas Central Nervous System, Oncology, Immunology, Dermatology, Metabolic Disorders and Ophthalmology which include indications Pancreatic Cancer, Solid Tumor, Alzheimer's Disease, Colorectal Cancer, Non-Small Cell Lung Cancer, Inflammatory Pain, Osteoarthritis Pain, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Amyotrophic Lateral Sclerosis, Bile Duct Cancer (Cholangiocarcinoma), Brain Cancer, Breast Cancer, Central Nervous System (CNS) Tumor, Fibrosarcoma, Neuroblastoma, Neuroendocrine Tumors, Ovarian Cancer, Pain, Pruritus, Salivary Gland Cancer, Anaplastic Large Cell Lymphoma (ALCL), Astrocytoma, Atopic Dermatitis, Biliary Tumor, Bladder Cancer, Cancer Pain, Chronic Pain, Colon Cancer, Diabetic Retinopathy, Gastric Cancer, Gastrointestinal Stromal Tumor (GIST), Glioblastoma Multiforme (GBM), Head And Neck Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Hepatocellular Carcinoma, Inflammation, Keratoconjunctivitis sicca (Dry Eye), Low Back Pain, Melanoma, Metastatic Colorectal Cancer, Metastatic Hepatocellular Carcinoma (HCC), Metastatic Melanoma, Multiple Sclerosis, Neuropathic Pain, Non-Small Cell Lung Carcinoma, Open-Angle Glaucoma, Pancreatic Ductal Adenocarcinoma, Papillary Thyroid Cancer, Plaque Psoriasis (Psoriasis Vulgaris), Pontine Glioma, Prostate Cancer, Psoriasis, Renal Cell Carcinoma, Retinitis Pigmentosa (Retinitis), Soft Tissue Sarcoma, Thymic Carcinoma, Thymoma (Thymic Epithelial Tumor) and Thyroid Cancer.

The latest report High Affinity Nerve Growth Factor Receptor - Pipeline Review, H1 2018, outlays comprehensive information on the High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140 TrkA or NTRK1 or EC 2.7.10.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140 TrkA or NTRK1 or EC 2.7.10.1) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The report provides a snapshot of the global therapeutic landscape for High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140 TrkA or NTRK1 or EC 2.7.10.1)
  • The report reviews High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140 TrkA or NTRK1 or EC 2.7.10.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140 TrkA or NTRK1 or EC 2.7.10.1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140 TrkA or NTRK1 or EC 2.7.10.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140 TrkA or NTRK1 or EC 2.7.10.1) targeted therapeutics
Reasons for Purchase:
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140 TrkA or NTRK1 or EC 2.7.10.1)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140 TrkA or NTRK1 or EC 2.7.10.1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Array BioPharma Inc
  • Daiichi Sankyo Co Ltd
  • Genzyme Corp
  • Ignyta Inc
  • Merck & Co Inc
  • Plexxikon Inc
  • MORE
Introduction

Report Coverage

High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140 TrkA or NTRK1 or EC 2.7.10.1) - Overview

High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140 TrkA or NTRK1 or EC 2.7.10.1) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140 TrkA or NTRK1 or EC 2.7.10.1) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140 TrkA or NTRK1 or EC 2.7.10.1) - Companies Involved in Therapeutics Development

Array BioPharma Inc

AstraZeneca Plc

Benevolentai Cambridge Ltd

Daiichi Sankyo Co Ltd

Dompe Farmaceutici SpA

Genzyme Corp

Handok Inc

Ignyta Inc

Loxo Oncology Inc

Merck & Co Inc

Nerviano Medical Sciences Srl

Pfizer Inc

Plexxikon Inc

Purdue Pharma LP

Rottapharm Biotech Srl

Sienna Biopharmaceuticals Inc

Tiziana Life Sciences Plc

High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140 TrkA or NTRK1 or EC 2.7.10.1) - Drug Profiles

ACD-855 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ARRY-954 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AZD-7451 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BNN-27 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cenegermin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CRB-0089 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DBPR-114 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DS-6051 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

entrectinib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GZ-389988 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

larotrectinib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

milciclib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Inhibit TrkA for Central Nervous System Disorders and Peripheral Nervous System Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NMSP-626 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NOV-1601 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pegcantratinib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PLX-7486 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit TrkA for Inflammatory Pain - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Agonize TrkA and TrkB for Alzheimer’s Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit TRK1 for Pain - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit TrkA for Inflammatory Pain - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SNA-125 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptide Agonize TrkA and TrkB Alzheimer's Disease and Amyotrophic Lateral Sclerosis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VM-902A - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140 TrkA or NTRK1 or EC 2.7.10.1) - Dormant Products

High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140 TrkA or NTRK1 or EC 2.7.10.1) - Discontinued Products

High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140 TrkA or NTRK1 or EC 2.7.10.1) - Product Development Milestones

Featured News & Press Releases

Apr 09, 2018: Tiziana Life Sciences Announces a Poster Presentation on Phase II clinical data with Milciclib in Thymic carcinoma and Thymoma patients at the American Society of Clinical Oncology (ASCO) Meeting (June 1-5, Chicago IL)

Mar 26, 2018: Bayer Announces Completion of Rolling Submission of New Drug Application in the U.S. for Larotrectinib for the Treatment of TRK Fusion Cancer

Mar 12, 2018: Sienna Biopharmaceuticals Announces First Patient Dosed in Proof-of-Concept Trial of Topical by Design JAK Inhibitor SNA-125 for Atopic Dermatitis

Feb 21, 2018: Loxo Oncology Announces Publication of Larotrectinib Clinical Data in The New England Journal of Medicine

Feb 14, 2018: Sienna Biopharmaceuticals Announces First Patient Dosed in First-in-Human Trial of Topical SNA-

Dec 21, 2017: Sundia Congratulates NHRI for DBPR114 IND Approval in US & Taiwan

Dec 20, 2017: Bayer announces initiation of rolling submission of new drug application in the U.S. for larotrectinib for the treatment of TRK fusion cancers

Dec 20, 2017: Loxo Oncology Initiates Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Larotrectinib for the Treatment of TRK Fusion Cancers

Dec 08, 2017: Tiziana Life Sciences Announces Safety of Milciclib in a Phase 2a Trial in Unresectable or Metastatic Hepatocellular Carcinoma (HCC) Patients

Dec 07, 2017: Bayer to Highlight New Oncology Research on larotrectinib at ASH

Dec 04, 2017: Updated larotrectinib pediatric clinical trial data demonstrate continued durability of response in TRK fusion cancers

Nov 23, 2017: Tiziana Life Sciences Announces that Milciclib Met its Primary Endpoint in Two Phase II Clinical Trials in Patients with Thymic Carcinoma and Thymoma”

Oct 24, 2017: Sienna Biopharmaceuticals Announces First Patient Dosed in Phase 2b Trial of Topical SNA-

Oct 19, 2017: AlzeCure to Present Data on NeuroRestore Project at 10th annual Conference on Clinical Trials for Alzheimer’s Disease (CTAD)

Oct 18, 2017: Loxo Oncology Announces Positive Top-Line Results from Independent Review Committee Assessment of Larotrectinib Dataset

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Indications, H1 2018

Number of Products under Development by Indications, H1 2018 (Contd..1), H1 2018

Number of Products under Development by Indications, H1 2018 (Contd..2), H1 2018

Number of Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Products under Development by Companies, H1 2018 (Contd..2), H1 2018

Products under Development by Companies, H1 2018 (Contd..3), H1 2018

Products under Development by Companies, H1 2018 (Contd..4), H1 2018

Number of Products under Investigation by Universities/Institutes, H1 2018

Products under Investigation by Universities/Institutes, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Pipeline by Array BioPharma Inc, H1 2018

Pipeline by AstraZeneca Plc, H1 2018

Pipeline by Benevolentai Cambridge Ltd, H1 2018

Pipeline by Daiichi Sankyo Co Ltd, H1 2018

Pipeline by Dompe Farmaceutici SpA, H1 2018

Pipeline by Genzyme Corp, H1 2018

Pipeline by Handok Inc, H1 2018

Pipeline by Ignyta Inc, H1 2018

Pipeline by Loxo Oncology Inc, H1 2018

Pipeline by Merck & Co Inc, H1 2018

Pipeline by Nerviano Medical Sciences Srl, H1 2018

Pipeline by Pfizer Inc, H1 2018

Pipeline by Plexxikon Inc, H1 2018

Pipeline by Purdue Pharma LP, H1 2018

Pipeline by Rottapharm Biotech Srl, H1 2018

Pipeline by Sienna Biopharmaceuticals Inc, H1 2018

Pipeline by Tiziana Life Sciences Plc, H1 2018

Dormant Products, H1 2018

Dormant Products, H1 2018 (Contd..1), H1 2018

Dormant Products, H1 2018 (Contd..2), H1 2018

Discontinued Products, H1 2018

Discontinued Products, H1 2018 (Contd..1), H1 2018

List of Figures

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Top 10 Indications, H1 2018

Number of Products by Mechanism of Actions, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Array BioPharma Inc
  • AstraZeneca Plc
  • Benevolentai Cambridge Ltd
  • Daiichi Sankyo Co Ltd
  • Dompe Farmaceutici SpA
  • Genzyme Corp
  • Handok Inc
  • Ignyta Inc
  • Loxo Oncology Inc
  • Merck & Co Inc
  • Nerviano Medical Sciences Srl
  • Pfizer Inc
  • Plexxikon Inc
  • Purdue Pharma LP
  • Rottapharm Biotech Srl
  • Sienna Biopharmaceuticals Inc
  • Tiziana Life Sciences Plc
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll